富亮氨酸重复激酶2抑制剂作为新型帕金森病治疗剂的研究进展  

Leucine-rich repeat kinase 2 inhibitor as Parkinson′s disease novel therapeutics:research advances

作　　者：战晓宇 任旭红[1] 何新华[2] 

机构地区：[1]沈阳药科大学制药工程学院,沈阳110016 [2]军事医学科学院毒物药物研究所,北京100850

出　　处：《国际药学研究杂志》2016年第1期97-103,133,共8页Journal of International Pharmaceutical Research

摘　　要：帕金森病(PD)是以多巴胺能神经系统退行性病变为特征的多因素疾病。对其进行分型研究,发展针对PD发病机制的治疗药物是提高PD治疗效果的必由之路。富亮氨酸重复激酶2(LRRK2)基因突变是部分家族遗传性PD和散发性PD的直接原因。LRRK2基因突变会导致LRRK2活性增加,进而导致神经退行性病变。因此,发展LRRK2抑制剂调控LRRK2活性有望成为新的PD治疗方法。LRRK2既是激酶,也是小GTP酶,存在2个药物作用位点,因此,目前LRRK2抑制剂有2类,一类是LRRK2激酶位点抑制剂,另一类是LRRK2 GTP结合位点抑制剂。本文综述了LRRK2及其抑制剂的研究进展。Parkinson＇s disease（PD） is a common disease caused by multiple factors and characterized by pathological degeneration in the dopaminergic neural system. Based on its pathogenic factors, PD can be divided into several subtypes, so it is essential to develop therapeutic agents based on the main pathogenic factor of each subtype of PD. Recently it is confirmed that the mutation of leucine-rich repeat kinase 2 （LRRK2） gene leads to increased activity of the LRRK2 notably, and then causes neurodegeneration. Thus developing LRRK2 inhibitors to modulate the kinase activity will be a novel therapy for the PD subtype which is caused by LRRK2 gene mutation. LRRK2, either a kinase or a GTPase, has two drug binding sites. Therefore, two types of LRRK2 inhibitors are being studied, one is the kinase inhibitor and the other is GTPase inhibitor. This paper summarizes the recent progress in the discovery and development of LRRK2 inhibitors.

关 键 词：帕金森病 富亮氨酸重复激酶2 富亮氨酸重复激酶2抑制剂 激酶结合位点 GTP结合位点 

分 类 号：R742.5[医药卫生—神经病学与精神病学]